Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study

• Maya Leventer-Roberts ,

  * E-mail: mayale3@clalit.org.il

  Affiliations Clalit Research Institute, Tel Aviv, Israel, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

  http://orcid.org/0000-0001-5797-0786

  ⨯
• Ariel Hammerman,

  Affiliation Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel

  ⨯
• Ilan Brufman,

  Affiliation Clalit Research Institute, Tel Aviv, Israel

  ⨯
• Moshe Hoshen,

  Affiliation Clalit Research Institute, Tel Aviv, Israel

  ⨯
• Marius Braun,

  Affiliations Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, Liver Unit, Beilinson Hospital, Petach Tikva, Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

  ⨯
• Yaffa Ashur,

  Affiliation Hepatology, Clalit Health Services, Tel Aviv, Israel

  ⨯
• Nicky Lieberman,

  Affiliation Community Medicine Division, Clalit Health Services, Tel Aviv, Israel

  ⨯
• Ran Balicer

  Affiliations Clalit Research Institute, Tel Aviv, Israel, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, Department of Epidemiology, Faculty of Health Sciences, Ben Gurion University, Be'er Sheva, Israel

  ⨯